Liraglutide showed no statistically significant difference in depression diagnoses for non-diabetic patients
The pooled GLP1-RA analysis demonstrated benefits in the secondary endpoints as well, with a 13% reduction in cardiovascular death [HR, 0.87 (0.800.94)], 10% reduction in MI [HR, 0.90 (0.830.98)], 17% reduction in stroke [HR, 0.83 (0.760.92)], 11% reduction in heart failure hospitalizations [HR, 0.89 (0.820.98)], and 12% reduction in all-cause mortality [HR, 0.88 (0.820.94)] [26]
Patients with a body mass index (BMI) of 30 or higher, or BMI of 27 or higher with weight-related health conditions like hypertension or type 2 diabetes, generally qualify for GLP-1 treatment
James Grant of Michigan BCBS summarized the frustration: "We were wasting millions of dollars, and people did not even see true benefit." From an actuarial perspective, the math was devastating